Clinical Trial Update: A Study in Patients With Non-cystic Fibrosis Bronchiectasis to Test How Well Different Doses of BI 1323495 Are Tolerated and How BI 1323495 Affects Biomarkers of Inflammation [Phase 1]

View source ↗

Summary

Phase 1 study evaluating tolerability of BI 1323495 across dose cohorts and its impact on inflammatory biomarkers in non-cystic fibrosis bronchiectasis; the tri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-cystic Fibrosis Bronchiectasis

Drugs mentioned

• BI 1323495

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Non-cystic Fibrosis Bronchiectasis | Phase 1 | Status: TERMINATED | Results posted: 2024-11-05